|title=Mesothelioma Molecular and Genetic Testing: BAP1, CDKN2A, NGS Panels & Biomarker-Guided Treatment
|description=Comprehensive guide to molecular and genetic testing for mesothelioma including BAP1 mutations, CDKN2A FISH, NF2 inactivation, n
...
55 KB (7,216 words) - 23:25, 14 May 2026
...leadership of the program and has pioneered research into the genomic and molecular basis of mesothelioma<ref name="nci_genetics" />.<ref name="dandell_maligna
* '''Advances immunotherapy combinations''' — Currently testing checkpoint inhibitors alongside targeted agents to exploit the specific gen
...
24 KB (3,109 words) - 19:06, 20 May 2026
...reference on immunohistochemistry markers, staging systems, and molecular testing, see '''[[Mesothelioma_Diagnosis_and_Staging]]'''.
...covering immunohistochemistry marker panels, TNM staging tables, molecular testing, and blood biomarker assays in detail.
...
24 KB (3,224 words) - 14:49, 2 May 2026
| style="padding:8px 10px; background:#f8f9fa; font-weight:bold;" | Germline testing
| style="padding:8px 10px;" | BAP1 germline testing — ASCO 2025 Strong Recommendation for all patients
...
39 KB (4,780 words) - 23:07, 14 May 2026
...logical subtypes, TNM 8th edition staging, blood biomarkers, and molecular testing.
...fication and stage groupings.<ref name="jtd_staging" /> Emerging molecular testing for '''BAP1''', '''CDKN2A''', and other genetic alterations is increasingly
...
58 KB (7,639 words) - 23:25, 14 May 2026
...ic test opened pathways for personalized treatment planning based on tumor molecular characteristics. The training programs he established have produced a gener
* '''Developed molecular tools for treatment decisions''' — The four-gene ratio test moved mesotheli
...
28 KB (3,564 words) - 23:25, 14 May 2026
...mmation. This multiplex approach far outperformed single-marker mesothelin testing (AUC 0.82, sensitivity 66%, specificity 88%) in the same populations. The D
High-Mobility Group Box 1 (HMGB1) is a damage-associated molecular pattern protein that plays a central role in asbestos carcinogenesis. When
...
38 KB (4,854 words) - 23:25, 14 May 2026
...histologic subtype, performance status, age, gender, blood biomarkers, and molecular characteristics such as germline BAP1 mutations.<ref name="seer-14k" /><ref
...ual outcomes vary dramatically based on stage, histology, age, gender, and molecular markers
...
45 KB (5,643 words) - 23:25, 14 May 2026
...emistry''' with standardized marker panels, conducting ancillary molecular testing including '''BAP1 loss''' and '''CDKN2A FISH''', and developing an evidence
...ioma from benign mesothelial proliferations when combined with CDKN2A FISH testing
...
60 KB (7,904 words) - 23:25, 14 May 2026
...-style:italic; border-bottom:1px solid #dee2e6;" | Prediagnostic Biomarker Testing for Mesothelioma
...re diagnosis, providing the prospective evidence base needed to move panel testing toward clinical surveillance programs.<ref name="bmjopen_diaphragm" /><ref
...
39 KB (5,126 words) - 23:25, 14 May 2026
...ation treatments like CAR T-cell therapy, and scientists investigating the molecular basis of the disease.<ref name="mesonet_treatment" />
...ns''' — patients seen by listed specialists gain access to 6 active trials testing CAR T-cell therapy, neoadjuvant immunotherapy, and gene therapy unavailable
...
61 KB (8,018 words) - 23:25, 14 May 2026
...stemic toxicity — a critical consideration for early-phase clinical safety testing.<ref name="pmcpotential" /><ref name="pubmedsterman98" />
...mal outlook provided both clinical rationale and ethical justification for testing novel and unproven therapeutic approaches in affected patients.<ref name="p
...
67 KB (8,772 words) - 23:06, 14 May 2026
...ncologist or thoracic-oncology multidisciplinary team. Methylation subtype testing is investigational and is not standard of care for mesothelioma treatment s
...European Society for Medical Oncology Scale for Clinical Actionability of molecular Targets (ESCAT), a retrospective predictive-biomarker study at this sample
...
36 KB (4,563 words) - 02:01, 24 May 2026
* '''BAP1/MTAP testing vs standard cytology alone''' — combined BAP1 and MTAP immunohistochemistry
...c evaluation of the fluid through cytology, biochemistry, and microbiology testing, and therapeutic relief of symptoms caused by large-volume fluid buildup in
...
69 KB (8,834 words) - 23:25, 14 May 2026
...million grant from the National Cancer Institute to fund ongoing biomarker testing to determine which [[Pleural Mesothelioma|pleural mesothelioma]] patients w
* Targeted therapies based on tumor molecular profiling
...
26 KB (3,165 words) - 23:26, 14 May 2026
...part of the initial IHC panel. Additionally, BAP1 loss and CDKN2A deletion testing are increasingly important for distinguishing malignant mesothelioma from w
...nd its strong general association with asbestos — combined with the shared molecular features between testicular and pleural mesothelioma — typically support co
...
50 KB (6,428 words) - 23:26, 14 May 2026
...ch Database:''' Total Cancer Care initiative enrolled 76,000+ patients for molecular profiling
Testing safety and efficacy of transarterial chemoperfusion treatment with cisplati
...
29 KB (3,447 words) - 23:25, 14 May 2026
...se relationships, and — where relevant — fiber burden analysis and genetic testing evidence.<ref name="dandell6" /><ref name="mesatty2" />
...e of a peritoneal mesothelioma to nivolumab and ipilimumab: a case report, molecular analysis and review of literature], PMC11291227, Frontiers in Oncology, 202
...
32 KB (3,931 words) - 23:26, 14 May 2026
...like acute occupational injuries, mesothelioma is a disease of accumulated molecular damage spanning decades.<ref name="mesonetlatency" />
...gnosis" or "missed earlier exposure."<ref name="shortlatencypmc" /> Modern molecular genetics has reframed short latency: germline mutations in DNA repair genes
...
53 KB (7,021 words) - 23:25, 14 May 2026
* '''ISM6331 AI-designed drug enters human testing''' — Insilico Medicine's pan-TEAD inhibitor reached first-in-human dosing i
Phase III trials represent the final stage of clinical testing before FDA approval. These large, randomized studies compare new treatments
...
111 KB (14,507 words) - 23:25, 14 May 2026
